Reid, K. F. http://orcid.org/0000-0001-9652-5319
Storer, T. W.
Pencina, K. M.
Valderrabano, R.
Latham, N. K.
Wilson, L.
Ghattas, C.
Dixon, R.
Nunes, A.
Bajdek, N.
Huang, G.
Skeels, S. E.
Lin, A. P.
Merugumala, S. M.
Liao, H. J.
Bouxsein, M. L.
Zafonte, R. D.
Bhasin, S.
Funding for this research was provided by:
National Institute of Child Health and Human Development (R01HD093724)
Boston Claude Pepper Older Americans Independence Center (P30AG31679)
Harvard Catalyst Translational Science Center (UL1TR002541)
Article History
Received: 11 April 2022
Accepted: 16 May 2022
First Online: 25 May 2022
Declarations
:
: The study was approved by the Mass General Brigham Institutional Review Board. A written informed consent will be obtained from all participants.
: Not applicable.
: SB reports receiving research grant support from AbbVie, Transition Therapeutics, FPT, and Metro International Biotechnology, Inc. and has received consulting fees from OPKO Pharmaceuticals and POXEL, Inc., and has equity interest in FPT, LLC and Xyone Therapeutics. Other authors report no conflicts of interest.